<?xml version="1.0" encoding="UTF-8"?>
<p id="Par7">Angiogenesis is essential for tumour growth and metastasis, and vascular endothelial growth factor (VEGF) is one of the most studied angiogenic factors. VEGF expression is associated with metastasis in NPC patients [
 <xref ref-type="bibr" rid="CR16">16</xref>, 
 <xref ref-type="bibr" rid="CR17">17</xref>]. Anti-VEGF antibody bevacizumab has direct anti-vascular effects with enhanced radiosensitivity [
 <xref ref-type="bibr" rid="CR18">18</xref>]. A phase II study showed that the addition of bevacizumab to standard chemoradiation treatment in NPC patients is feasible and could delay the progression of subclinical distant disease [
 <xref ref-type="bibr" rid="CR19">19</xref>].
</p>
